Physician profile
Amanda M Ferrer
NPI 1720516719
$1,481.44
in general payments reported to CMS, 2019-2025
19 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.89 · 2020: $109 · 2021: $371 · 2022: $75.34 · 2023: $285 · 2024: $365 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $268.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $190.15 | 2021-2023 | |
| Lilly USA, LLC | $175.35 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $159.66 | 2020-2025 | Trelegy Ellipta |
| Abbvie INC. | $150.68 | 2020-2021 | |
| Coloplast Corp | $110.32 | 2021 | |
| Exact Sciences Corporation | $94.20 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $76.32 | 2019-2024 | Prolia, Evenity, Repatha |
| Allergan, INC. | $39.65 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $31.25 | 2024 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $28.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.96 | 2022 | |
| Sanofi Pasteur INC. | $22.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.70 | 2025 | |
| Mylan Specialty L.P. | $21.58 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.15 | 2021 | |
| Merck Sharp & Dohme LLC | $14.04 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ferrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.